|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM112698115 |
| 003 |
DE-627 |
| 005 |
20250202155245.0 |
| 007 |
tu |
| 008 |
231222s1996 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0376.xml
|
| 035 |
|
|
|a (DE-627)NLM112698115
|
| 035 |
|
|
|a (NLM)11363825
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Eradication of HIV
|b the cutting edge of clinical trial design
|
| 264 |
|
1 |
|c 1996
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.09.1996
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Newspaper Article
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Pyridines
|2 NLM
|
| 650 |
|
7 |
|a Lamivudine
|2 NLM
|
| 650 |
|
7 |
|a 2T8Q726O95
|2 NLM
|
| 650 |
|
7 |
|a Zidovudine
|2 NLM
|
| 650 |
|
7 |
|a 4B9XT59T7S
|2 NLM
|
| 650 |
|
7 |
|a Indinavir
|2 NLM
|
| 650 |
|
7 |
|a 5W6YA9PKKH
|2 NLM
|
| 650 |
|
7 |
|a Zalcitabine
|2 NLM
|
| 650 |
|
7 |
|a 6L3XT8CB3I
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Critical Path AIDS project
|d 1994-1995
|g (1996), No 31 vom: 06., Seite 16-7
|w (DE-627)NLM098213636
|x 1085-7605
|7 nnns
|
| 773 |
1 |
8 |
|g year:1996
|g number:No 31
|g day:06
|g pages:16-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 1996
|e No 31
|b 06
|h 16-7
|